Arcturus Therapeutics (NASDAQ: ARCT) reported Q1 EPS of ($0.52), $4.11 worse than the analyst estimate of $3.59. Revenue for the quarter came in at $29.38 million versus the consensus estimate of $205.21 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.